111150-22-2

111150-22-2 structure

Name: NF 110
Chemical Name: NF 110,4,4',4'',4'''-[Carbonylbis[imino-5,1,3-benzenetriylbis(carbonylimino)]]tetrakisbenzenesulfonicacidtetrasodiumsalt
CAS Number: 111150-22-2
Molecular Formula: C₄₁H₂₈N₆Na₄O₁₇S₄
Molecular Weight: 1096.91000
Catalog: Signaling Pathways Membrane Transporter/Ion Channel P2X Receptor
Create Date: 2016-01-21 00:27:56
Modify Date: 2025-08-27 12:58:51
NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1].

Name	NF 110,4,4',4'',4'''-[Carbonylbis[imino-5,1,3-benzenetriylbis(carbonylimino)]]tetrakisbenzenesulfonicacidtetrasodiumsalt
Synonyms	nf110

Description	NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> P2X Receptor Research Areas >> Neurological Disease
Target	Ki: 36 nM (P2X3 Receptor)
In Vitro	NF110 shows an activity in the human tumour cell line panel, with IC30 of 362.3 μM[2]. NF110 inhibits HMGA2-DNA interactions with an IC50 of 0.87 μM[3].
In Vivo	NF110 shows potency at Endogenous P2X Receptors in Rat DRG Neurons, with a peak amplitude of 675 pA[1].
References	[1]. Hausmann R, et al. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69(6):2058-2067. [2]. Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36(6):803-809. [3]. Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10(1):18850. Published 2020 Nov 2.